PBL awared further US patents on short RNAi molecules

21-Jul-2014 - Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 8,759,102 and US Patent No. 8,779,236 with fundamental claims directed to RNAi in cells and organisms to effect gene silencing. These two new patents granted add to the ...

PBL awarded two US patents on RNAi

17-Sep-2012 - Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of inducing ...

US Patent Granted for Verona Pharma’s RPL554

29-Aug-2012 - Verona Pharma plc announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554. The patent is the fourth patent issued for RPL554 and related compounds in the US.RPL554, Verona Pharma's lead drug candidate, is a dual ...

New Patents Issued to Diffusion Pharmaceuticals

Lead drug trans sodium crocetinate receives new patent protection through 2027

20-Aug-2012 - Diffusion Pharmaceuticals LLC announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled “Bipolar Trans Carotenoids Salts and Their Uses” and “Trans Carotenoids, Their Synthesis and Uses,” respectively. These patents include compound, ...

Thermo Fisher Scientific Awarded Patent for Cell Factory System

02-Feb-2012 - Thermo Fisher Scientific Inc. announced that it has been awarded a patent by the United States Patent and Trademark Office on its Thermo Scientific Nunc Cell Factory System with Active Gassing, recognizing the device’s unique gas distribution system. Developed for cells that require a high or low ...

MorphoSys Strengthens Patent Position on MOR202 Program

25-Jan-2012 - MorphoSys AG announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled ...

Plant Bioscience Limited awarded US patent on RNAi

19-Jan-2012 - Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,097,710 with fundamental claims directed to methods of inducing gene silencing using short RNA molecules, or DNA constructs encoding short RNA molecules, in a wide ...

Pharming granted U.S. patent on C1 inhibitor use in ischemia reperfusion injury indications

20-Dec-2011 - Pharming Group NV announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent 8,071,532, covering a method of preventing, reducing or treating an ischemia and/or reperfusion injury by administering recombinant C1 inhibitor (Ruconest®/ Rhucin®). The ...

Critical Outcome Technologies Inc. Receives U.S. Patent for Promising Oncology Compound COTI-2

17-Oct-2011 - Critical Outcome Technologies Inc. (COTI) announced that a composition of matter patent has been granted by the United States Patent and Trademark Office (USPTO) on October 11, 2011, representing a major milestone for the Company and its most advanced oncology drug candidate, COTI-2.“The granting ...

Affitech A/S strengthens its IP portfolio on anti-VEGF antibody AT001/r84

14-Oct-2011 - Affitech A/S announced that the U.S. Patent and Trademark Office (USPTO) has granted Affitech U.S. patent (no. 8,034,905) covering the Company’s anti-VEGF antibody drug candidate AT001/r84. The newly granted US patent is the first patent grant Affitech has received for this compound in a major ...